Scotiabank began coverage on shares of Avidity Biosciences (NASDAQ:RNA – Free Report) in a report issued on Friday morning, ...

Fintel reports that on March 7, 2025, Scotiabank initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Sector ...

Scotiabank analyst Louise Chen initiated coverage of Avidity Biosciences (RNA) with an Outperform rating and $70 price target The firm sees a ...

Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report)’s stock price gapped down before the market opened on Monday after Barclays lowered their price target on the stock from $63.00 to $57.00. The ...

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), ...

Friday - Cantor Fitzgerald reaffirmed its Overweight rating and $96.00 price target for Avidity Biosciences (NASDAQ:RNA) stock, representing significant upside from the current ...

Just a few weeks after Avidity Biosciences made a stir with new data on its experimental therapy for Duchenne muscular dystrophy, the biotech has closed a public offering that raised an impressive ...

Colossal Biosciences, a Texas-based company, genetically engineered a woolly mouse, marking an achievement toward its goal of resurrecting extinct species like the woolly mammoth. The woolly mouse ...

Feetures, America's #1 running sock, is dedicated to supporting athletes of all ages and promoting the importance of being ...

Note :Financial Information is based on numbers. Note :Financial Information is based on numbers. Note :Financial Information is based on numbers. Note :Financial ...

We're fourth in the UK in terms of the quality of our research (REF 2021). In the REF 2021, 98 per cent of research and impact from the School of Biosciences has been classed as world-leading or ...

Story Jan. 10 - Shoreline Biosciences: The cell therapy biotech plans to let go of an undisclosed number of employees tied to a project with Gilead Sciences’ Kite Pharma. Story Jan. 9 - IGM ...